Walleye Capital
PCSA icon

Walleye Capital’s Processa Pharmaceuticals PCSA Stock Holding History

Walleye Capital’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-839
Closed -$107K – 5371
2023
Q3 		$107K Buy
839
+106
+14% +$20K ﹤0.01% 3914
2023
Q2 		$182K Sell
733
-735
-50% -$217K ﹤0.01% 3139
2023
Q1 		$389K Buy
+1,468
New +$591K 0.01% 1910

Other funds holding PCSA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.62B AUM 36.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Walleye Capital's PCSA Position: Q4 2023 in Review

Walleye Capital sold out of Processa Pharmaceuticals (PCSA) in Q4 2023, closing a stake of 839 shares — an estimated $107K sold.

Walleye Capital first reported a position in PCSA in Q1 2023 and held it in 3 quarters. The position peaked at $389K in Q1 2023. 18 funds tracked by Wall St. Rank hold PCSA as of Q4 2023.

  • Walleye Capital reported no remaining Processa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Walleye Capital sold 839 Processa Pharmaceuticals shares in Q4 2023, an estimated $107K.
  • Walleye Capital first reported a position in Processa Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Walleye Capital's Processa Pharmaceuticals position peaked at $389K in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.